Loading
A phase 1 trial of WTX-124 run by Werewolf Therapeutics, Inc., completed.
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT05479812 by Werewolf Therapeutics, Inc., with 156 participants enrolled, started 2022-08-15. Conditions recorded: Metastatic Solid Tumor and Advanced Solid Tumor. Interventions recorded: WTX-124 and pembrolizumab.
Shares Werewolf Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Werewolf Therapeutics and the tag pipeline.
Shares Werewolf Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/